UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000030770 |
|---|---|
| Receipt number | R000035133 |
| Scientific Title | An evaluation study of decreasing effect of uncomfortable feelings in nose and eyes by consumption of plant extract |
| Date of disclosure of the study information | 2018/01/14 |
| Last modified on | 2018/05/01 12:56:31 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
An evaluation study of decreasing effect of uncomfortable feelings in nose and eyes by consumption of plant extract
Acronym
An evaluation study of decreasing effect of uncomfortable feelings in nose and eyes by consumption of plant extract
Scientific Title
An evaluation study of decreasing effect of uncomfortable feelings in nose and eyes by consumption of plant extract
Scientific Title:Acronym
An evaluation study of decreasing effect of uncomfortable feelings in nose and eyes by consumption of plant extract
Region
| Japan |
Condition
Condition
Healthy adult
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To confirm the decreasing effect of uncomfortable feelings in nose and eyes by long term consumption of plant extract.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Japan Rhinoconjunctivitis Quality of Life Questionnaire (JRQLQ)
Key secondary outcomes
Secondary outcomes: nasal eosinophils, nonspecific IgE, Allergen-specific IgE (for 16 allergens), histamine, TNF-alpha.
Safety evaluation outcomes: physiological examination, hematological examination, blood biochemical examination, urine examination, presence or absence of side effects and adverse events during the test.
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Food |
Interventions/Control_1
Intake 60 mL of test food a day, 12 consecutive weeks.
Interventions/Control_2
Intake 60 mL of placebo food a day, 12 consecutive weeks.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 59 | years-old | > |
Gender
Male and Female
Key inclusion criteria
(1)Male and female aged 20 to 59 when consent acquisition.
(2)Subjects who can intake test food every day.
(3)Subjects who notice themselves as they are mild/moderate hay fever and/or perennial allergic rhinitis.
(4)Subjects giving written informed consent.
Key exclusion criteria
(1) Subjects who have treated or taken medicine for perennial allergic rhinitis from 4 weeks before advance inspection to the end of the study.
(2) Subjects who planning some treatment during the examination period.
(3) Subjects who intake the medicines, the foods for specified health uses (FOSHU) and/or the health foods those are concerned their influence to test results.
(4) Pregnant or expected pregnant, and lactating women.
(5) Subjects who have previous and/or current medical history of serious disease in heart, liver, kidney.
(6) Subjects who excessive alcohol intake.
(7) Subjects who have smoking habit.
(8) Subjects who have extremely irregular dining habits, and subjects who have midnight work or irregular shift work.
(9) Subjects who have previous medical history of drug and/or food, allergy, especially for Shiso leaf.
(10) Subjects who are participating the other clinical tests. Subjects who participated within 4-weeks prior to the current study and/or who plan to participate the other clinical tests.
(11) Subjects who donated over 200mL blood and/or blood components within the last one month to the current study.
(12) Subjects who donated over 400mL blood and/or blood components within the last three month to the current study.
(13) Females who donated over 400mL blood and/or blood components within the last four month to the current study.
(14) Males who will be collected over 1200mL blood and/or blood components, when the sampling amounts within the last twelve month are adding to the planned sampling amounts of this study.
(15) Females who will be collected over 800mL blood and/or blood components when, the sampling amounts within the last twelve month are adding to the planned sampling amounts of this study.
(16) Others who have been determined ineligible by principal investigator or sub-investigator.
Target sample size
50
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Suguru Fujiwara |
Organization
CPCC Co., Ltd.
Division name
Clinical Research Planning Department
Zip code
Address
4F Chusin Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, JAPAN
TEL
03-5297-3112
cpcc-contact@cpcc.co.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Makoto Ichinohe |
Organization
CPCC Co., Ltd.
Division name
Sales & Planning division
Zip code
Address
4F Chusin Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, JAPAN
TEL
03-5297-3112
Homepage URL
cpcc-contact@cpcc.co.jp
Sponsor or person
Institute
CPCC Company Limited
Institute
Department
Personal name
Funding Source
Organization
Emotent Co., Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2018 | Year | 01 | Month | 14 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2017 | Year | 12 | Month | 21 | Day |
Date of IRB
Anticipated trial start date
| 2018 | Year | 01 | Month | 15 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2018 | Year | 01 | Month | 11 | Day |
Last modified on
| 2018 | Year | 05 | Month | 01 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035133
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
